FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136192561> ?p ?o ?g. }

• W3136192561 endingPage "S509" @default.
• W3136192561 startingPage "S509" @default.
• W3136192561 abstract "IntroductionDespite lung re-transplantation is becoming more frequent, it continues to present several challenges in regards to the management of immunosuppression and infectious risks.We present a case of invasive aspergillosis that highlights the risks associated with increasing immunosuppression after re-transplantation due to antibody-mediated rejection (AMR).Case ReportPatient is 30 years-old male who underwent primary bilateral lung transplant in December 2016 due to H1N1 Influenza and respiratory failure. His immunosuppression regimen included tacrolimus, prednisone and mycophenolate mofetil (MMF). In June 2018, the patient developed evidence of a significant lung function decline, multiple de novo donor-specific antibodies, including DR17 and DQ2, and acute cellular rejection along with endarteritis on lung biopsy. His initial AMR therapy protocol included intravenous immunoglobulin (IVIG), plasmapheresis, rabbit anti-thymocyte globulin and carfilzomib. Due to the persistence of circulating DSAs and lung function decline, he received also rituximab and monthly belatacept. Eventually, the patient underwent re-transplantation due to chronic lung allograft dysfunction in June 2019. His immunosuppression included tacrolimus, prednisone, MMF, IVIG and belatacept. In November 2019, the patient developed headache, blurry vision and seizure. He was found to have a left parietal lobe abscess requiring resection (figure 1A). Pathology and cultures confirmed the presence of Aspergillus fumigatus. Belatacept and MMF were held. He was treated successfully for 12 months with voriconazole with resolution of symptoms and improved brain imaging (figure 1B).SummaryThe management of immunosuppression in the setting of AMR and re-transplantaion poses several challenges. However, lung re-transplantation remains an ethically justified measures in highly selected patients. Despite lung re-transplantation is becoming more frequent, it continues to present several challenges in regards to the management of immunosuppression and infectious risks. We present a case of invasive aspergillosis that highlights the risks associated with increasing immunosuppression after re-transplantation due to antibody-mediated rejection (AMR). Patient is 30 years-old male who underwent primary bilateral lung transplant in December 2016 due to H1N1 Influenza and respiratory failure. His immunosuppression regimen included tacrolimus, prednisone and mycophenolate mofetil (MMF). In June 2018, the patient developed evidence of a significant lung function decline, multiple de novo donor-specific antibodies, including DR17 and DQ2, and acute cellular rejection along with endarteritis on lung biopsy. His initial AMR therapy protocol included intravenous immunoglobulin (IVIG), plasmapheresis, rabbit anti-thymocyte globulin and carfilzomib. Due to the persistence of circulating DSAs and lung function decline, he received also rituximab and monthly belatacept. Eventually, the patient underwent re-transplantation due to chronic lung allograft dysfunction in June 2019. His immunosuppression included tacrolimus, prednisone, MMF, IVIG and belatacept. In November 2019, the patient developed headache, blurry vision and seizure. He was found to have a left parietal lobe abscess requiring resection (figure 1A). Pathology and cultures confirmed the presence of Aspergillus fumigatus. Belatacept and MMF were held. He was treated successfully for 12 months with voriconazole with resolution of symptoms and improved brain imaging (figure 1B). The management of immunosuppression in the setting of AMR and re-transplantaion poses several challenges. However, lung re-transplantation remains an ethically justified measures in highly selected patients." @default.
• W3136192561 created "2021-03-29" @default.
• W3136192561 creator A5086729197 @default.
• W3136192561 date "2021-04-01" @default.
• W3136192561 modified "2023-09-27" @default.
• W3136192561 title "Challenges in Lung Re-Transplantation Following Antibody-Mediated Rejection" @default.
• W3136192561 doi "https://doi.org/10.1016/j.healun.2021.01.2057" @default.
• W3136192561 hasPublicationYear "2021" @default.
• W3136192561 type Work @default.
• W3136192561 sameAs 3136192561 @default.
• W3136192561 citedByCount "1" @default.
• W3136192561 countsByYear W31361925612021 @default.
• W3136192561 crossrefType "journal-article" @default.
• W3136192561 hasAuthorship W3136192561A5086729197 @default.
• W3136192561 hasBestOaLocation W31361925611 @default.
• W3136192561 hasConcept C141071460 @default.
• W3136192561 hasConcept C159654299 @default.
• W3136192561 hasConcept C203014093 @default.
• W3136192561 hasConcept C2778720950 @default.
• W3136192561 hasConcept C2778842783 @default.
• W3136192561 hasConcept C2780252810 @default.
• W3136192561 hasConcept C2780303639 @default.
• W3136192561 hasConcept C2780653079 @default.
• W3136192561 hasConcept C2780743877 @default.
• W3136192561 hasConcept C2781307858 @default.
• W3136192561 hasConcept C2781448352 @default.
• W3136192561 hasConcept C2909675724 @default.
• W3136192561 hasConcept C2911091166 @default.
• W3136192561 hasConcept C2994498544 @default.
• W3136192561 hasConcept C71924100 @default.
• W3136192561 hasConceptScore W3136192561C141071460 @default.
• W3136192561 hasConceptScore W3136192561C159654299 @default.
• W3136192561 hasConceptScore W3136192561C203014093 @default.
• W3136192561 hasConceptScore W3136192561C2778720950 @default.
• W3136192561 hasConceptScore W3136192561C2778842783 @default.
• W3136192561 hasConceptScore W3136192561C2780252810 @default.
• W3136192561 hasConceptScore W3136192561C2780303639 @default.
• W3136192561 hasConceptScore W3136192561C2780653079 @default.
• W3136192561 hasConceptScore W3136192561C2780743877 @default.
• W3136192561 hasConceptScore W3136192561C2781307858 @default.
• W3136192561 hasConceptScore W3136192561C2781448352 @default.
• W3136192561 hasConceptScore W3136192561C2909675724 @default.
• W3136192561 hasConceptScore W3136192561C2911091166 @default.
• W3136192561 hasConceptScore W3136192561C2994498544 @default.
• W3136192561 hasConceptScore W3136192561C71924100 @default.
• W3136192561 hasIssue "4" @default.
• W3136192561 hasLocation W31361925611 @default.
• W3136192561 hasOpenAccess W3136192561 @default.
• W3136192561 hasPrimaryLocation W31361925611 @default.
• W3136192561 hasRelatedWork W1649350133 @default.
• W3136192561 hasRelatedWork W1807270846 @default.
• W3136192561 hasRelatedWork W1964145194 @default.
• W3136192561 hasRelatedWork W2095137960 @default.
• W3136192561 hasRelatedWork W2341875091 @default.
• W3136192561 hasRelatedWork W2376833857 @default.
• W3136192561 hasRelatedWork W2508659662 @default.
• W3136192561 hasRelatedWork W2884231047 @default.
• W3136192561 hasRelatedWork W3136192561 @default.
• W3136192561 hasRelatedWork W4313466463 @default.
• W3136192561 hasVolume "40" @default.
• W3136192561 isParatext "false" @default.
• W3136192561 isRetracted "false" @default.
• W3136192561 magId "3136192561" @default.
• W3136192561 workType "article" @default.